DNA X CFO granted 35,000 restricted stock units

DNA X, Inc. reported that its Chief Financial Officer, Clayton Crolius, received a grant of 35,000 restricted stock units of common stock on February 9, 2026 at a price of $0.00 per share.

Rhea-AI Filing Summary

DNA X, Inc. reported that its Chief Financial Officer, Clayton Crolius, received a grant of 35,000 restricted stock units of common stock on February 9, 2026 at a price of $0.00 per share. These units vest in equal monthly installments over one year, conditioned on continued service.

Each restricted stock unit represents the right to receive one share of common stock. After this grant, Crolius beneficially owns 36,719 securities, consisting of 1,719 shares of common stock and 35,000 unvested restricted stock units. The filing notes these figures reflect a 1-for-18 reverse stock split effective October 27, 2025.

Insider Trade Summary

Grant/Award: 35,000 shares

Grant/Award 1 txn

Insider Crolius Clayton

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	35,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 36,719 shares (Direct)

Footnotes (3)

1. F1. Represents the grant of restricted stock units that vest in equal monthly installments over a one-year period following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.
2. F2. Consists of (i) 1,719 shares of common stock and (ii) 35,000 unvested restricted stock units.
3. F3. The number of securities reported herein reflects the effects of a 1-for-18 reverse stock split effected by the Issuer on October 27, 2025, which was exempt from reporting pursuant to Rule 16a-9.

FAQ

What did DNA X (SONM) disclose in this Form 4 for its CFO?

DNA X reported a stock-based grant to its CFO. Clayton Crolius received 35,000 restricted stock units on February 9, 2026, at $0.00 per share, vesting monthly over one year, increasing his beneficial holdings to 36,719 securities including existing common shares.

How many DNA X (SONM) shares and units does the CFO now beneficially own?

The CFO beneficially owns 36,719 securities in total. This consists of 1,719 shares of common stock and 35,000 unvested restricted stock units, each unit representing the right to receive one share of DNA X common stock upon vesting.

What are the vesting terms of the 35,000 restricted stock units at DNA X (SONM)?

The 35,000 restricted stock units vest over one year. They vest in equal monthly installments following the February 9, 2026 grant date, and vesting requires the CFO’s continued service to DNA X throughout the vesting period.

Was there a reverse stock split mentioned in the DNA X (SONM) Form 4?

Yes, the filing references a reverse stock split. The number of securities reported reflects a 1-for-18 reverse stock split that DNA X effected on October 27, 2025, which the filing notes was exempt from reporting under Rule 16a-9.

Did the CFO of DNA X (SONM) pay cash for the newly granted restricted stock units?

No cash was paid for the restricted stock unit grant. The 35,000 restricted stock units were reported at a price of $0.00 per share, indicating they were awarded as equity compensation rather than purchased in an open-market or cash transaction.

What role does the reporting person hold at DNA X (SONM) in this Form 4?

The reporting person serves as Chief Financial Officer. Clayton Crolius is identified as an officer of DNA X, holding the title Chief Financial Officer, and the Form 4 indicates the transaction involves his directly owned securities of the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/10/2026 - 08:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crolius Clayton

(Last) (First) (Middle)

C/O DNA X, INC.

4445 EASTGATE MALL, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DNA X, Inc. [ SONM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		A		35,000(1)	A	$0.00	36,719(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the grant of restricted stock units that vest in equal monthly installments over a one-year period following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.

2. Consists of (i) 1,719 shares of common stock and (ii) 35,000 unvested restricted stock units.

3. The number of securities reported herein reflects the effects of a 1-for-18 reverse stock split effected by the Issuer on October 27, 2025, which was exempt from reporting pursuant to Rule 16a-9.

	/s/ Clay Crolius	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.